Zobrazeno 1 - 10
of 13
pro vyhledávání: '"David Ramies"'
Autor:
Shringi Sharma, Xavier Pepin, Harini Burri, Lianqing Zheng, Nataliya Kuptsova‐Clarkson, Anouk de Jong, Ting Yu, Holly L. MacArthur, Michal Majewski, John C. Byrd, Richard R. Furman, Joseph A. Ware, James Mann, David Ramies, Veerendra Munugalavadla, Louise Sheridan, Helen Tomkinson
Publikováno v:
Clinical pharmacology in drug development. 11(11)
Acalabrutinib is a Bruton tyrosine kinase (BTK) inhibitor approved to treat adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or previously treated mantle cell lymphoma. As the bioavailability of the acalabrutinib capsule (AC) dep
Autor:
Catherine Diefenbach, James Essell, Ji Cheng, Andy I. Chen, Tycel Phillips, Franck Morschhauser, Mark Brunvand, David Ramies, Annalisa Chiappella, Ian W. Flinn, Jamie Hirata
Publikováno v:
American Journal of Hematology. 97
Autor:
Annalisa Chiappella, Tycel Phillips, David Ramies, Andy I. Chen, Franck Morschhauser, Catherine Diefenbach, Ian W. Flinn, Jamie Hirata, Mark Brunvand, James Essell, Ji Cheng
Publikováno v:
SSRN Electronic Journal.
Background: Single-agent polatuzumab vedotin (pola) and obinutuzumab (G) demonstrated safety/clinical activity in separate B-cell non-Hodgkin lymphoma (B-NHL) trials. Methods: Open-label, non-randomised, phase 1b/2 study (ROMULUS) of patients with re
Autor:
James Mann, Nataliya Kuptsova-Clarkson, Holly L MacArthur, Shringi Sharma, David Ramies, Michal Majewski, Anouk de Jong, Veerendra Munugalavadla, Harini Burri, Helen Tomkinson, Xavier Pepin, Lianqing Zheng, Joseph Ware, Ting Yu, Louise Sheridan
Publikováno v:
Blood. 138:4365-4365
Introduction: Acalabrutinib (Calquence ®), a selective Bruton tyrosine kinase (BTK) inhibitor, is approved for the treatment of mantle cell lymphoma (relapsed/refractory) and chronic lymphocytic leukemia. Patients with hematologic malignancies may r
Autor:
Joanne Li, Riccardo Spezia, Brenda W. Cooper, Michael Kenneth Keng, David Ramies, Erica D. Warlick, Silvia Mappa, Samer K. Khaled, Ehab Atallah
Publikováno v:
Journal of Clinical Oncology. 38:7556-7556
7556 Background: Hypomethylating agents (HMA), such as azacitidine (AZA), are the standard of care for patients (pts) with higher-risk myelodysplastic syndromes (MDS). However, overall response rate (ORR=CR+PR) with HMA alone is approximately 30%, wi
Publikováno v:
Blood. 134:4767-4767
Objectives: Worsening of symptoms by oncology treatment can adversely affect QoL. The MD Anderson Symptom Inventory (MDASI) is a patient-reported outcome capturing the severity of symptoms and their interference with daily living (activity, working,
Autor:
Michael K Keng, David Ramies, Ehab Atallah, Brenda W. Cooper, Erica D. Warlick, Samer K. Khaled, Silvia Mappa
Publikováno v:
Blood. 132:4362-4362
Introduction: Higher risk MDS is a serious disease associated with poor survival with hypomethylating agents (HMAs) the standard of care in patients ineligible for stem cell transplantation. Unfortunately, HMAs are only effective in 30-40% of patient
Autor:
Linh, Nguyen, Jaymes, Holland, David, Ramies, Richard, Mamelok, Natacha, Benrimoh, Sabrina, Ciric, Thomas, Marbury, Richard A, Preston, Douglas M, Heuman, Edith, Gavis, Steven, Lacy
Publikováno v:
Journal of clinical pharmacology. 56(9)
Cabozantinib is a tyrosine kinase inhibitor approved for the treatment of patients with progressive, metastatic medullary thyroid cancer. Two clinical pharmacology studies were conducted to characterize single-dose pharmacokinetics (PK) of cabozantin
Autor:
O. Melnyk, Lowell L. Hart, Alan B. Sandler, David Ramies, Vincent J. O'Neill, Ming Lin, Philip Bonomi, Roy S. Herbst, Chandra P. Belani, Louis Fehrenbacher
Publikováno v:
Journal of Clinical Oncology. 25:4743-4750
Purpose Bevacizumab, a humanized anti–vascular endothelial growth factor monoclonal antibody, and erlotinib, a reversible, orally available epidermal growth factor receptor tyrosine kinase inhibitor, have demonstrated evidence of a survival benefit
Autor:
Bert L. Lum, Daniel A. Laheru, Theresa Rogers, N. Senzer, Wells A. Messersmith, Manuel Hidalgo, Sean K. Kelley, David Ramies, Paula Grouleff, Ross C. Donehower
Publikováno v:
Clinical Cancer Research. 10:6522-6527
Purpose: This phase I study was conducted to establish the dose-limiting toxicities and maximum-tolerated dose of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in combination with FOLFIRI, a standard regimen of irinot